Adaptimmune Therapeutics PLC
ADAP0.074USD
-0.005-6.76%
交易中 （美东）报价延迟15分钟
115.26M总市值
亏损市盈率 TTM
关于 Adaptimmune Therapeutics PLC 公司
Adaptimmune Therapeutics PLC 是一家临床阶段的生物制药公司。该公司专注于为癌症患者提供细胞疗法。其工程化 T 细胞受体 (TCR) 平台能够对 T 细胞进行工程化，以靶向和摧毁多种实体肿瘤类型的癌症。其细胞疗法候选药物包括 TCR T 细胞和 TruC T 细胞。其产品候选药物包括 afamitresgene autoleucel (afami-cel) 和 Lete-cel。afamicel 是一种细胞疗法，可为滑膜肉瘤患者提供治疗选择。该公司正在过渡 lete-cel，该疗法针对滑膜肉瘤和粘液样圆细胞脂肪肉瘤 (MRCLS) 患者的 NY-ESO 抗原。其临床管线包括 ADP-A2M4CD8 的 SURPASS-III II 期试验和 ADP-A2M4CD8 的 SURPASS I 期试验。该公司最先进的临床前项目是针对 PRAME 靶点 (ADP-600) 和 CD70 (ADP-520) 的 T 细胞疗法。ADAP-600 是一种工程化的 TCR T 细胞。
公司简介
公司代码ADAP
公司名称Adaptimmune Therapeutics PLC
上市日期May 06, 2015
CEOMr. Adrian Rawcliffe
员工数量506
证券类型Depository Receipt
年结日May 06
公司地址60 Jubilee Avenue
城市ABINGDON
上市交易所NASDAQ Capital Market Consolidated
国家United Kingdom
邮编OX14 4RX
电话441235430000
网址https://www.adaptimmune.com/
公司代码ADAP
上市日期May 06, 2015
CEOMr. Adrian Rawcliffe
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
611.22K
+191.15%
Mr. John Lunger
Mr. John Lunger
Chief Patient Supply Officer
Chief Patient Supply Officer
170.89K
+53.91%
Dr. Elliot Norry, M.D.
Dr. Elliot Norry, M.D.
Chief Medical Officer
Chief Medical Officer
133.26K
+99.32%
Ms. Cintia Piccina
Ms. Cintia Piccina
Chief Commercial Officer
Chief Commercial Officer
111.07K
+559.70%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Non-Executive Independent Director
Non-Executive Independent Director
23.89K
--
Mr. Adrian Rawcliffe
Mr. Adrian Rawcliffe
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. William C. (Bill) Bertrand, Jr., Esq.
Mr. William C. (Bill) Bertrand, Jr., Esq.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. John P. Furey
Mr. John P. Furey
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Joanna Brewer, Ph.D.
Dr. Joanna Brewer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
611.22K
+191.15%
Mr. John Lunger
Mr. John Lunger
Chief Patient Supply Officer
Chief Patient Supply Officer
170.89K
+53.91%
Dr. Elliot Norry, M.D.
Dr. Elliot Norry, M.D.
Chief Medical Officer
Chief Medical Officer
133.26K
+99.32%
Ms. Cintia Piccina
Ms. Cintia Piccina
Chief Commercial Officer
Chief Commercial Officer
111.07K
+559.70%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Non-Executive Independent Director
Non-Executive Independent Director
23.89K
--
Mr. Adrian Rawcliffe
Mr. Adrian Rawcliffe
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月21日 周三
更新时间: 5月21日 周三
持股股东
股东类型
持股股东
持股股东
占比
EcoR1 Capital, LLC
10.34%
Long Focus Capital Management LLC
8.96%
Two Seas Capital LP
7.75%
New Enterprise Associates (NEA)
6.44%
MPM Capital Inc.
2.01%
Other
64.50%
持股股东
持股股东
占比
EcoR1 Capital, LLC
10.34%
Long Focus Capital Management LLC
8.96%
Two Seas Capital LP
7.75%
New Enterprise Associates (NEA)
6.44%
MPM Capital Inc.
2.01%
Other
64.50%
股东类型
持股股东
占比
Hedge Fund
18.51%
Investment Advisor/Hedge Fund
16.32%
Venture Capital
6.44%
Research Firm
1.46%
Investment Advisor
1.40%
Individual Investor
0.63%
Pension Fund
0.07%
Other
55.17%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
191
118.83M
44.83%
-43.82M
2025Q1
196
118.11M
44.76%
-44.66M
2024Q4
195
128.66M
50.28%
-22.55M
2024Q3
199
155.41M
60.76%
-9.79M
2024Q2
202
157.35M
61.56%
-15.41M
2024Q1
213
165.17M
64.85%
-7.14M
2023Q4
210
146.11M
64.44%
-17.89M
2023Q3
229
151.45M
66.86%
-8.97M
2023Q2
226
147.93M
65.80%
+13.35M
2023Q1
200
118.51M
71.56%
-15.30M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
EcoR1 Capital, LLC
27.40M
10.34%
--
--
Mar 31, 2025
Long Focus Capital Management LLC
23.76M
8.96%
+3.26M
+15.92%
Mar 31, 2025
Two Seas Capital LP
20.53M
7.75%
+5.69M
+38.39%
Mar 31, 2025
New Enterprise Associates (NEA)
17.08M
6.44%
--
--
Apr 11, 2025
MPM Capital Inc.
5.34M
2.01%
-219.75K
-3.96%
Mar 31, 2025
MPM BioImpact LLC
4.89M
1.85%
-201.57K
-3.96%
Mar 31, 2025
Morgan Stanley & Co. LLC
2.63M
0.99%
+1.62M
+159.49%
Mar 31, 2025
Rock Springs Capital Management LP
2.48M
0.94%
--
--
Mar 31, 2025
Acadian Asset Management LLC
2.22M
0.84%
+1.71M
+334.76%
Mar 31, 2025
Renaissance Technologies LLC
1.81M
0.68%
-712.66K
-28.21%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Fidelity Enhanced Small Cap ETF
0%
ActivePassive International Equity ETF
0%
SPDR S&P International Small Cap ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
Simplify Propel Opportunities ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
iShares Biotechnology ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
Fidelity Enhanced Small Cap ETF
占比0%
ActivePassive International Equity ETF
占比0%
SPDR S&P International Small Cap ETF
占比0%
Invesco NASDAQ Future Gen 200 ETF
占比0%
SPDR Portfolio Developed World ex-US ETF
占比0%
Simplify Propel Opportunities ETF
占比0%
ProShares Ultra Nasdaq Biotechnology
占比0%
iShares Biotechnology ETF
占比0%
Invesco Nasdaq Biotechnology ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
